Overview
Familial Creutzfeldt-Jakob disease (fCJD) is a rare, inherited prion disease. It is characterized by rapidly progressive neurodegeneration, leading to dementia, ataxia, and myoclonus.Diagnosis
Diagnosis is typically based on clinical presentation, supported by neuroimaging (MRI), electroencephalogram (EEG), and cerebrospinal fluid (CSF) analysis for 14-3-3 protein.
Genetic testing to identify mutations in the prion protein gene (PRNP) is definitive for familial forms.Management
There is no cure or specific treatment for fCJD. Management is supportive and palliative, focusing on symptom relief and quality of life.
Symptomatic treatment may include anticonvulsants for myoclonus and anxiolytics for agitation.Special Populations
Genetic counseling is crucial for affected families due to the autosomal dominant inheritance pattern.
Disclosure of genetic information to family members can be complex, with normative documents offering varying guidance on balancing patient confidentiality and family notification 1.Key Recommendations
Genetic testing for PRNP mutations is recommended for suspected cases of familial CJD 1. (Evidence: Expert opinion)
Management of fCJD is primarily supportive, aiming to alleviate symptoms and maintain patient comfort 1. (Evidence: Expert opinion)
Healthcare professionals face challenges in navigating the disclosure of genetic information to family members when patients do not consent, with existing normative documents providing insufficient clarity 1. (Evidence: Weak)References
1 Phillips A, Borry P, Van Hoyweghen I, Vears DF. Disclosure of genetic information to family members: a systematic review of normative documents. Genetics in medicine : official journal of the American College of Medical Genetics 2021. link